Breaking News Instant updates and real-time market news.

GE

General Electric

$17.90

-1.12 (-5.89%)

, HD

Home Depot

$168.06

2.71 (1.64%)

16:21
11/14/17
11/14
16:21
11/14/17
16:21

On The Fly: Top stock stories for Tuesday

Stocks opened deep in negative territory and saw their lows a short time after the open. The early weakness was attributed to a hotter than expected producer prices report. The PPI strength was attributed to the impact of the hurricanes in September but analysts will be watching tomorrow's consumer prices report for confirmation of the inflationary data. By midday the averages had cut their losses in half and then drifted for the remainder of the day. ECONOMIC EVENTS: In the U.S., the Producer Price Index rose 0.4% in both the headline and core readings for October, which was hotter than expected inflation data. The NFIB small business optimism index rose 0.8% to 103.8 in October. In Europe, Germany's Q3 GDP data came in stronger than expected, rising 2.8% from the prior year, while broader Eurozone Q3 GDP growth was about in-line with expectations. Eurostat confirmed a preliminary estimate that Eurozone gross domestic product grew 2.5% on a year-over-year basis from July to September. In Asia, China's October data was a bit softer than expected. Industrial production rose 6.2% and retail sales climbed 10%, both of which were a bit below the consensus forecasts. COMPANY NEWS: Shares of General Electric (GE) were down for the second consecutive day as analysts issued their reactions to yesterday's guidance cut and dividend reduction at the industrial giant. Among them, RBC Capital analyst Deane Dray downgraded GE to Sector Perform and cut his price target to $20 from $25, saying that he now expects the turnaround at the company to be more protracted than previously anticipated. GE shares slipped another 6% today after the stock had declined by more than 7% yesterday... Shares of Home Depot (HD), another member of the Dow, rose 1.4% after it reported stronger than expected comparable sales growth, driven in part by recovery efforts following recent hurricane activity, and raised its fiscal year profit outlook... Meanwhile, Envision Healthcare (EVHC) shares surged 10% after Bloomberg reported that the company has attracted buyout interest from firms including Carlyle Group (CG) and Onex. The private equity groups may bid for the company alone or as part of a group, sources told Bloomberg. MAJOR MOVERS: Among the notable gainers was Buffalo Wing Wings (BWLD), which jumped 24% after The Wall Street Journal reported that the restaurant chain owner has received a takeover bid from private-equity firm Roark Capital. Also higher was Advance Auto Parts (AAP), which gained 16% after its quarterly earnings topped expectations. Among the noteworthy losers was Loxo Oncology (LOXO), which dropped 4% after the company announced a partnership with Bayer (BAYRY) to develop and commercialize its two lead cancer-fighting drugs. Also lower following their earnings reports were Dicks Sporting Goods (DKS), which fell 3%, and Switch (SWCH), which dropped 5.25%. INDEXES: The Dow fell 30.23, or 0.13%, to 23,409.47, the Nasdaq lost 19.72, or 0.29%, to 6,737.87, and the S&P 500 declined 5.97, or 0.23%, to 2,578.87.

GE

General Electric

$17.90

-1.12 (-5.89%)

HD

Home Depot

$168.06

2.71 (1.64%)

EVHC

Envision Healthcare

$28.52

2.66 (10.29%)

CG

Carlyle Group

$20.65

-0.525 (-2.48%)

BWLD

Buffalo Wild Wings

$145.35

28.1 (23.97%)

AAP

Advance Auto Parts

$95.72

13.44 (16.33%)

LOXO

Loxo Oncology

$79.84

-3.39 (-4.07%)

BAYRY

Bayer

$32.01

0.23 (0.72%)

DKS

Dick's Sporting

$25.59

-0.73 (-2.77%)

SWCH

Switch

$18.95

-1.08 (-5.39%)

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 16

    Nov

  • 29

    Nov

  • 06

    Dec

  • 20

    Feb

GE General Electric
$17.90

-1.12 (-5.89%)

11/14/17
COWN
11/14/17
NO CHANGE
COWN
Market Perform
Woodward may have negative read through from GE Power guidance, says Cowen
Cowen analyst Guatam Khanna noted that General Electric (GE) has reduced its outlook for its Power segment and said it will seek to pare back delivery of gas turbine part orders that have already been placed. All of this may add pressure to Woodward's (WWD) FY18 industrial segment guidance, said Khanna, who has a Market Perform rating on Woodward shares.
11/14/17
11/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Deane Dray saying that he now expects the turnaround at the company to be more protracted than previously anticipated, noting the roadmap laid out by new CEO John Flannery fell short of expectations regarding the scope of the business model/portfolio changes. 2. Phillips 66 (PSX) downgraded to Underweight from Equal Weight at Barclays analyst Paul Cheng saying the company's diversified business model will likely drive underperformance in a strong margin uptrend environment for U.S. refiners. 3. Hilton (HLT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Stephen Grambling citing the recent outperformance of the stock for the rating change, but he expects consistent double-digit earnings growth on low single-digit RevPAR. 4. PulteGroup (PHM) downgraded to Neutral from Buy at Buckingham with the firm citing recent share strength and raised its price target to $33 from $31. 5. Albemarle (ALB) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter downgraded Albemarle (ALB) to Hold from Buy while raising his price target for the shares to $150 from $130. Following a field trip to China, Begleiter believes new lithium processing capacity is coming, which should begin to pressure prices by 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
BOFA
11/14/17
NO CHANGE
Target $23
BOFA
Buy
BofA/Merrill sticking with a Buy on General Electric
BofA/Merrill analyst Andrew Obin said General Electric's dividend cut and lowered 2018 outlook are a "true reset" while the $6B pension refunding in 2018 through debt issuance should reduce some of the concerns about off-balance sheet liabilities. Obin said the company is focused on the core portfolio and is evaluating other options withing its portfolio, where there is significant optionality. The analyst did cut his estimates and reduced his price target on General Electric shares to $23 from $27 but is sticking with his Buy rating.
11/14/17
RBCM
11/14/17
DOWNGRADE
Target $20
RBCM
Sector Perform
GE downgraded to Sector Perform at RBC Capital on protracted turnaround
As reported earlier, RBC Capital analyst Deane Dray downgraded General Electric to Sector Perform from Outperform and cut his price target to $20 from $25. Dray says that he now expects the turnaround at the company to be more protracted than previously anticipated, noting the roadmap laid out by new CEO John Flannery fell short of expectations regarding the scope of the business model/portfolio changes. The analyst says the investment community was especially disappointed by the scope of the "missteps and secular challenges", as well as the systemic cash flow shortfalls, in the Power segment, along with the disclosure that the company's dividend payout was above the scope of industrial cash flows for several years.
HD Home Depot
$168.06

2.71 (1.64%)

11/06/17
KEYB
11/06/17
INITIATION
KEYB
Sector Weight
Home Depot initiated with a Sector Weight at KeyBanc
KeyBanc analyst Bradley Thomas initiated Home Depot with a Sector Weight citing limited upside to current valuation.
11/07/17
11/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Michael Kors (KORS) resumed with a Neutral at BofA/Merrill. 2. Lowe's (LOW) was initiated with an Overweight at KeyBanc while Home Depot (HD) was initiated with a Sector Weight. 3. OptiNose (OPTN) was initiated with an Outperform at BMO Capital and RBC Capital, an Overweight at Piper Jaffray, and a Buy at Jefferies. 4. LendingClub (LC) initiated with a Buy at Maxim. 5. LKQ Corp. (LKQ) initiated with an Outperform at Wolfe Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
STFL
11/14/17
NO CHANGE
STFL
Buy
Home Depot should trade higher on Q3 report, says Stifel
Stifel analyst John Baugh offered a quick take on Home Depot's Q3 report, saying he believes the stronger than expected comparable sales growth should send the stock higher even though it had moved up in advance of the report. He maintains a Buy rating on Home Depot shares, which are roughly flat in pre-market trading right before the market open.
11/14/17
BARD
11/14/17
NO CHANGE
Target $185
BARD
Outperform
Home Depot price target raised to $185 from $175 at Baird
Baird analyst Peter Benedict raised his estimates and increased his price target on Home Depot to $185 from $175 after the company reported "strong" Q3 results, stating that he thinks its "best-in-class execution" and "superior fundamentals" can continue supporting the stock's premium valuation. Benedict keeps an Outperform rating on Home Depot shares.
EVHC Envision Healthcare
$28.52

2.66 (10.29%)

11/14/17
KEYB
11/14/17
NO CHANGE
Target $40
KEYB
Overweight
Envision Healthcare target raised to $40 after buyout interest report at KeyBanc
After Bloomberg reported that Envision Healthcare has attracted buyout interest from firms, KeyBanc analyst Jason Gurda said he believes that a P/E buyer could reasonably bid "in the low $40s" for Envision in a leveraged buyout. The analyst, who added that he was not surprised to hear there is private equity interest in Envision, raised his price target on the stock to $40 from $37 and keeps an Overweight rating on the name.
11/14/17
OPCO
11/14/17
NO CHANGE
OPCO
Envision Healthcare could be worth up to $50/share, says Oppenheimer
11/14/17
OPCO
11/14/17
NO CHANGE
Target $40
OPCO
Outperform
Envision buyout price could approach $50 per share, says Oppenheimer
After Bloomberg reported that private equity firms Carlyle Group (CG) and Onex have shown interest, Oppenheimer analyst Michael Wiederhorn says he believes a buyout offer for Envision Healthcare could approach $50 per share. The stock in afternoon trading is up 8% to $27.96. Such an offer is based on an 11 times 2018 EBITDA estimate, which is multiple similar to the one paid by Blackstone (BX) for Team Health in late 2016, Wiederhorn tells investors in a research note. The analyst believes Envision has a "strong growth business" and he recommends continuing to buy the shares at current levels. Wiederhorn has an Outperform rating on Envision with a $40 price target.
11/14/17
BARD
11/14/17
NO CHANGE
Target $35
BARD
Outperform
Envision Healthcare LBO 'upside risk' underappreciated, says Baird
Baird analyst Whit Mayo said he would guess that about three to four hedge funds now collectively own about 20% of Envision Healthcare, with "potentially more in the shadows," and that an LBO is "very doable" if one believes there is an investment case for industry volumes. If there is a case seen for structural changes in volumes, cash collections and/or physician rate, Mayo sees the potential for "very acceptable returns" on a theoretical LBO in the $40 per share "area," he tells investors. Mayo, who thinks the "upside risk" of an LBO is being underappreciated, keeps an Outperform rating and $35 price target on Envision Healthcare shares.
CG Carlyle Group
$20.65

-0.525 (-2.48%)

10/10/17
SBSH
10/10/17
DOWNGRADE
Target $25.5
SBSH
Neutral
Carlyle Group downgraded to Neutral from Buy at Citi
Citi analyst William Katz downgraded Carlyle Group to Neutral citing valuation with the shares up 60% year-to-date. The analyst keeps a $25.50 price target for the shares.
10/10/17
10/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HSBC (HSBC) downgraded to Underperform from Neutral at Credit Suisse with analyst Sanjay Jain citing valuation. 2. Jabil Circuit (JBL) downgraded to Sell from Neutral at Goldman Sachs with analyst Mark Delaney saying street expectations, which assume Jabil's earnings grow double digits year-over-year for both of the next two years, are overly optimistic. 3. Carlyle Group (CG) downgraded to Neutral from Buy at Citi with analyst William Katz citing valuation with the shares up 60% year-to-date. 4. Eli Lilly (LLY) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying the valuation looks full with the shares up 13% since mid-August. 5. Ralph Lauren (RL) downgraded to Sell from Hold at Miller Tabak. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
BOFA
06/08/17
UPGRADE
BOFA
Buy
Carlyle Group upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded Carlyle Group (CG) to Buy saying the outlook for alternative asset managers is improving following a challenging 2015 and 2016. The analyst highlights "healthy" fundraising, improving returns, and rising distributions for the space. Carrier raised his price target for Carlyle to $21 from $20 while noting that Apollo Global (APO) remains his top pick in the space.
BWLD Buffalo Wild Wings
$145.35

28.1 (23.97%)

11/14/17
FBCO
11/14/17
NO CHANGE
Target $120
FBCO
Neutral
Buffalo Wild Wings takeover offer a modest surprise, says Credit Suisse
After The Wall Street Journal reported that private equity firm Roark Capital has made a $150/share offer for Buffalo Wild Wings, Credit Suisse analyst Jason West says he views the offer as a modest surprise given the latter's negative same store sales and margins trends in recent years. The analyst reiterates a Neutral rating on Buffalo Wild Wings' shares.
11/14/17
MAXM
11/14/17
NO CHANGE
Target $160
MAXM
Buy
Buffalo Wild Wings may receive a bid competing with Roark Capital, says Maxim
Maxim analyst Stephen Anderson notes yesterday's press speculation of a bid for Buffalo Wild Wings from Roark Capital, saying that while the $150/share price is "plausible", there is potential for a competing bid given the company-specific initiatives to cut expenses and an improving food cost climate. Anderson says that despite the industry headwinds and the pending exit of CEO Sally Smith, the company is laying the groundwork for a return to SSS growth, margin expansion, and increased shareholder returns. The analyst also says the recent decline in spot wing costs, already down 15% since summer end, will add to EPS next year. Anderson keeps his Buy rating and $160 price target on Buffalo Wild Wings.
11/14/17
WELS
11/14/17
NO CHANGE
Target $150
WELS
Market Perform
Buffalo Wild Wings price target raised to $150 from $110 at Wells Fargo
Wells Fargo analyst Jeff Farmer raised his price target for Buffalo Wild Wings to $150 from $110 after The Wall Street Journal reported that Roark made a takeover offer "of more than $150 a share in recent weeks." The analyst believes that a potential Roark acquisition coming to fruition is driven by Roark's history within the restaurant space, Buffalo Wild Wings' woeful fundamentals across both same-store sales and EPS, the relatively ineffective activist investor and leadership void. Farmer reiterates a Market Perform rating on the shares.
11/14/17
STFL
11/14/17
NO CHANGE
Target $115
STFL
Hold
Roark a credible buyer, Buffalo Wild Wings may be a willing seller, says Stifel
After The Wall Street Journal reported that Buffalo Wing Wings has received a takeover bid from private-equity firm Roark Capital, Stifel analyst Chris O'Cull said he thinks Roark could be a credible buyer given its success with several restaurant investments, including Wingstop, and that BWW could be a willing seller given Marcato's involvement and the company's recent struggles defining a clear vision for improving shareholder value. O'Cull has a Hold rating and $115 price target on Buffalo Wild Wings shares.
AAP Advance Auto Parts
$95.72

13.44 (16.33%)

11/08/17
MSCO
11/08/17
NO CHANGE
Target $92
MSCO
Overweight
Morgan Stanley admits to being wrong on Advance Auto Parts, but sees bottom near
Morgan Stanley analyst Simeon Gutman, in a note to investors partially titled "A Mea Culpa, But No Downgrade," admits he has been wrong so far on Advance Auto Parts' turnaround, but also believes the stock is close to a bottom. While he expects a "poor Q3 and lower guidance," he does not believe it will be as bad as the market expects, he tells investors. Gutman, who lowered his price target on Advance Auto shares to $92 from $100, keeps an Overweight rating on the stock citing his continued belief the company can narrow its EBIT margin gap with its peers.
10/04/17
10/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AutoNation (AN) downgraded to Neutral from Buy at Northcoast with analyst John Healy citing the recent strength in shares. 2. Winnebago (WGO) downgraded to Hold from Buy at Stifel with analyst Michael Baudendistel saying he believes new products and efficiency improvements will help drive near-term growth better than industry average, but he also thinks such expectations are more than fully priced into the stock. 3. Advance Auto Parts (AAP) downgraded to Market Perform at Raymond James with analyst Dan Wewer citing growing business risks facing the profit recovery story. 4. Cedar Fair (FUN) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Christopher Prykull saying he sees less upside to consensus estimate with rainy weather hurting amusement park results from Memorial Day to Labor Day. 5. Alcoa (AA) downgraded to Hold from Buy at Gabelli with the firm saying the cycle may be "long in the tooth," valuation is less compelling, and a Rio Tinto (RIO) merger is less likely until prices normalize. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/17
RAJA
10/04/17
DOWNGRADE
RAJA
Market Perform
Advance Auto Parts downgraded to Market Perform at Raymond James
Raymond James analyst Dan Wewer downgraded Advance Auto Parts to Market Perform from Strong Buy citing growing business risks facing the profit recovery story. The analyst is concerned that management initiatives to improve EBIT% and ROIC may lead to market share losses if not properly executed. They include tightening the policy for accepted product returns, increasing the number of stores district managers must supervise, and a reduction in gross inventory level by 20%. The analyst adds the company is on track to double its stores in Florida, which represents 8% of the store base, and could make it difficult to achieve its FY21 goal of mid-single-digit comp sales growth due to increasing competitive overlap.
09/15/17
09/15/17
NO CHANGE

Wolfe calls it 'way too early' to think about LBOs for most auto part
Wolfe Research analyst Chris Bottiglieri noted that auto part retailers have been "spookily rebounding" despite his survey pointing to negative investor sentiment, leading him to revisit his LBO model to assess take-out risk for the group. He concludes that while Advance Auto Parts (AAP) is entering a valuation range where an LBO is "in the discussion," he sees it as still "way too early" to consider the possibility of an LBO for O'Reilly Automotive (ORLY), AutoZone (AZO) or Genuine Parts (GPC). While Advance Auto shareholder Starboard may not sanction a deal that locks in losses, his estimated holding cost of $154 for the firm is a "soft floor" for a take-out price, he added.
LOXO Loxo Oncology
$79.84

-3.39 (-4.07%)

11/14/17
11/14/17
UPGRADE
Target $95

Outperform
Loxo Oncology upgraded after 'transformative' Bayer pact at JMP Securities
As previously reported, JMP Securities analyst Michael King upgraded Loxo Oncology (LOXO) to Outperform from Market Perform after the company announced a global partnership with Bayer (BAYRY) to develop and commercialize larotrectinib and LOXO-195. While he understands there is some disappointment that the deal fell short of a full buyout, King sees the partnership with a global leader in cancer treatment as "transformative" for Loxo, he tells investors. King set a $95 price target on Loxo shares, which are down 7% to $77.18 in afternoon trading.
11/14/17
IFSG
11/14/17
UPGRADE
Target $155
IFSG
Strong Buy
Loxo Oncology upgraded to Strong Buy from Outperform at IFS Securities
IFS Securities analyst David Bouchey upgraded Loxo Oncology to Strong Buy and raised his price target for the shares to $155 from $115. The company this morning announced a global partnership with Bayer (BAYRY) to develop and commercialize larotrectinib and LOXO-195. JMP Securities also upgraded Loxo intraday.
11/14/17
JMPS
11/14/17
UPGRADE
Target $95
JMPS
Outperform
Loxo Oncology upgraded to Outperform from Market Perform at JMP Securities
JMP Securities analyst Michael King upgraded Loxo Oncology (LOXO) to Outperform from Market Perform and set a $95 price target on the stock after the company announced a global partnership with Bayer (BAYRY) to develop and commercialize larotrectinib and LOXO-195.
11/14/17
COWN
11/14/17
NO CHANGE
COWN
Outperform
Loxo agreement in best interest of shareholders, says Cowen
Cowen analyst Eric Schmidt says that while Loxo Oncology's (LOXO) collaboration with Bayer (BAYRY) "will turn a few heads" since it includes 50% of U.S. rights, it represents a "solid monetization" of the company's TRK inhibitor franchise. Further, the analyst notes optimism before the agreement that Loxo might be an acquisition candidate ahead of larotrectinib's 2018 launch could be contributing to today's selloff. The deal is in the best interests of shareholders and $1B in nearer-term payments is substantial, Schmidt contends. He believes the agreement can be seen as one that monetizes a good portion of the TRK franchise value for upfront cash. The analyst keeps an Outperform rating on Loxo Oncology. The stock in early trading is down 5% to $79.11.
BAYRY Bayer
$32.01

0.23 (0.72%)

10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
DKS Dick's Sporting
$25.59

-0.73 (-2.77%)

11/10/17
CLVD
11/10/17
NO CHANGE
CLVD
Neutral
Dick's Sporting lacks a compelling catalyst, says Cleveland Research
Cleveland Resarch analyst Daryl Boehringer said Dicks's Sporting Goods is maintaining an aggressive stance thorugh the holiday season indicating the company will disappoint due to the high level of promotional activity. The analyst lowered second half estimates telling investors earnings will be below Street expectations pressured by "margin headwinds." Boehringer has a Neutral rating on shares.
11/14/17
ADAM
11/14/17
NO CHANGE
Target $24
ADAM
Hold
Dick's Sporting price target lowered to $24 from $27 at Canaccord
Canaccord analyst Camilo Lyon lowered his price target on Dick's Sporting Goods to $24 from $27 after the company broke with its prior precedent to give initial 2018 EPS guidance of up to a 20% decline on flat comparable sales. While he agrees that the company's investments should drive long-term benefits, the company must still navigate an uncertain retail environment and risk remains that further retail disruption could derail the recovery in the athletic industry, said Lyon, who keeps a Hold rating on Dick's shares.
11/06/17
OTRG
11/06/17
DOWNGRADE
OTRG
Negative
Dick's Sporting downgraded to Negative from Mixed at OTR Global
11/10/17
NOMU
11/10/17
NO CHANGE
Target $9
NOMU
Reduce
Under Armour price target lowered to $9 from $13 at Nomura Instinet
Nomura Instinet analyst Simeon Siegel cut his price target for Under Armour (UAA) to $9 and keeps a Reduce rating on the shares. With the recent sales decline, Under Armour is no longer a growth company, and yet it has maintained, and actually expanded, its multiple, Siegel tells investors in a research note. The latest quarterly filing indicates sales at Dick's Sporting Goods (DKS), Under Armour's top U.S. partner, declined 13% at best, Siegel contends. He believes that "North America declines appear hard to escape" and remains concerned over a further re-rating downward in the shares.
SWCH Switch
$18.95

-1.08 (-5.39%)

10/31/17
BTIG
10/31/17
INITIATION
Target $22
BTIG
Buy
Switch initiated with a Buy at BTIG
BTIG analyst Edward Parker started Switch with a Buy rating and $22 price target.
10/31/17
RAJA
10/31/17
INITIATION
RAJA
Market Perform
Switch initiated with a Market Perform at Raymond James
Raymond James analyst Frank Louthan initiated Switch with a Market Perform telling investors risk/reward is balanced.
10/31/17
WBLR
10/31/17
INITIATION
WBLR
Outperform
Switch initiated with an Outperform at William Blair
William Blair analyst Jim Breen started Switch with an Outperform rating saying the migration of IT infrastructure from on-premises data centers to hyperscale multitenant facilities is still in the early stages. The analyst sees "continued high demand" for Switch's properties. He believes a premium valuation is warranted and views the shares as attractive at current levels.
10/31/17
10/31/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ollie's Bargain Outlet (OLLI) initiated with an Overweight at Stephens. 2. Switch (SWCH) initiated with an Outperform at William Blair, Credit Suisse, and BMO Capital, an Overweight at JPMorgan, a Buy at BTIG, a Market Perform at Raymond James and Wells Fargo, a Neutral at Citi and Goldman Sachs, as well as a Hold at Jefferies. 3. iRadimed (IRMD) reinitiated with a Buy at Roth Capital. 4. Northstar Realty Europe (NRE) initiated with a Buy at FBR Capital. 5. Altice USA (ATUS) initiated with an Overweight at Atlantic Equities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.